We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 295.00 | 290.00 | 300.00 | 295.00 | 295.00 | 295.00 | 5,668 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.13 | 384M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/10/2016 15:55 | timbo003 let's hope Cyan does the same soon! | davep4 | |
27/10/2016 08:56 | This week's (unexpected) performance has to be worth an animated gif! As much as I would have liked to have attended the AGM yesterday, I think travelling over to the Maryland in the US would have been beyond the call of duty given the size of my modest holding | timbo003 | |
14/10/2016 15:47 | Thanks Banshee I hope they do better than the most recent "Best Technology" award winners, for example: * 2015 award winner: Advanced Oncotherapy (down > 45% in 12 months) * 2014 award winner: Rex Bionics (down > 85% in 24 months) * 2013 award winner: Wandisco (down > 85% in 36 months). &n | timbo003 | |
13/10/2016 21:45 | Hey guys, you have just won the Aim Technology Company of the Year award for 2016, don't all cheer at once :) | banshee | |
27/9/2016 11:41 | Thanks oshy I see there's an updated research note here: | timbo003 | |
27/9/2016 11:36 | Morning, short TV interview for Maxcyte's results announced this morning hxxp://fmp-tv.co.uk/ | oshy92 | |
27/9/2016 07:47 | Finals out today, they look okay to me, but I am not that well up on the business (yet) There is an analyst telecom today with slides available on the web site later (see below) This evening they are presenting at the Shares Magazine Investor Seminar (near Tower Hill tube) along with 3 others, so I will go along to that one, it starts at around 18.00 (see details in last post) #################### Conference call for analysts A briefing for analysts will be held at 11.00am BST on 27 September 2016 at the offices of Panmure Gordon & Co., One New Change, London, EC4M 9AF. There will be a simultaneous live conference call with Q&A and the presentation will be available on MaxCyte's website at Dial-in details: Participant dial-in: 08006940257 International dial-in: +44 (0) 1452 555566 Participant code: 86595211 An audio replay file will be made available shortly afterwards via the Company website: | timbo003 | |
04/9/2016 07:50 | Maxcyte will be presenting at the Shares Mag investor evening on September 27th I've already booked my place. | timbo003 | |
13/7/2016 23:08 | There's a new interview with MaxCyte CEO, Doug Doerfler on Directors talk He will be visiting London in September. so hopefully that will include an investor road show (I have a growing list of questions I want to ask). | timbo003 | |
13/7/2016 14:43 | MaxCyte Inc (LON:MXCT) Chief executive Doug Doerfler very confident over prospects for the current year. 13th July 2016 | dice1950 | |
12/7/2016 10:04 | Encouraging trading statement this morning. Also a new research note out with a target price of 184p/share | timbo003 | |
12/7/2016 08:53 | MaxCyte Right here, right now: catching the CAR-T wave 12th July 2016 MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy. | dice1950 | |
12/7/2016 08:53 | !YOUTUBEVIDEO:gMdn00 MaxCyte Right here, right now: catching the CAR-T wave 12th July 2016 MaxCyte is already delivering strong revenue growth, due to demand for its flow electroporation devices in drug discovery and cell therapy. MaxCyte Scalable High Throughput Transfection | dice1950 | |
16/5/2016 18:30 | There's a new video interview on ProactiveInvestors with Doug Doerfler (MaxCyte CEO) which is well worth a look, he seems very excited about their CARMA technology platform, the first product (to showcase the technology) is effective in Mouse and should be ready for the clinic (platinum resistant ovarian cancer) in H2/2017 | timbo003 | |
04/5/2016 20:14 | There's a useful article over on Proactiveinvestors (dated May 2nd) which explains why Maxcyte (a US based company) went for an AIM IPO rather than a Nasdaq IPO. | timbo003 | |
04/4/2016 09:42 | Thanks oshy, that was very helpful. | timbo003 | |
04/4/2016 09:19 | Morning, Short TV clip on MaxCyte: www.fmp-tv.co.uk/com | oshy92 | |
29/3/2016 18:49 | That was a good start to life on Aim, up circa 10% with only three trades (total 2,407 shares traded). All a bit academic for me, as this needs to be a three year hold for the tax breaks. | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions